
==== Front
Surg Today
Surg Today
Surgery Today
0941-1291
1436-2813
Springer Nature Singapore Singapore

38546862
2819
10.1007/s00595-024-02819-9
Original Article
Lung cancer after kidney transplantation: a 50-year experience at a single institution
http://orcid.org/0009-0000-7856-5843
Watanabe Hiroki hwatanabe@med.nagoya-u.ac.jp

1
Kadomatsu Yuka 1
Hakiri Shuhei 2
Yoshioka Hiromu 2
Hiramitsu Takahisa 3
Futamura Kenta 3
Okada Manabu 3
Goto Norihiko 3
Narumi Shunji 3
Watarai Yoshihiko 3
Chen-Yoshikawa Toyofumi Fengshi 1
1 https://ror.org/04chrp450 grid.27476.30 0000 0001 0943 978X Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550 Japan
2 grid.413410.3 0000 0004 0378 3485 Department of Thoracic Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, 2-9 Myoken-Cho, Syowa-Ku, Nagoya, 466-8650 Japan
3 grid.413410.3 0000 0004 0378 3485 Department of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan
28 3 2024
28 3 2024
2024
54 10 11241130
17 11 2023
22 1 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Purpose

To investigate the clinical characteristics of lung cancer that develops after kidney transplantation.

Methods

The clinical data of patients with lung cancer diagnosed after kidney transplantation were collected retrospectively. The medical records were extracted from our database. All patients underwent routine chest examination after kidney transplantation.

Results

In total, 17 lung tumors were detected in 15 (0.6%) of 2593 patients who underwent kidney transplantation at our institution. Eleven lung tumors were completely resected from a collective 10 patients (surgical group). The remaining five patients did not receive surgical treatment (nonsurgical group). The surgical group underwent wedge resection (n = 5), segmentectomy (n = 1), lobectomy (n = 3), and bilobectomy (n = 1). The pathological stages were 0 (n = 1), IA1 (n = 2), IA2 (n = 4), IA3 (n = 2), and IB (n = 1). The surgical group had a significantly better prognosis than the nonsurgical group. There were no perioperative complications related to kidney transplantation in either group.

Conclusions

Routine chest examination would be useful for the early diagnosis and treatment of lung cancer after kidney transplantation. Moreover, surgical resection for early-stage lung cancer was associated with a better prognosis for kidney transplantation patients.

Keywords

Lung cancer
Kidney transplantation
Thoracic surgery
Thoracic malignancies
Nagoya UniversityOpen Access funding provided by Nagoya University.

issue-copyright-statement© Japan Surgical Society 2024
==== Body
pmcIntroduction

Kidney transplantation for end-stage kidney disease is superior to dialysis in terms of quality and quantity of life and cost. Immunosuppressive agents are used to prevent graft failure after kidney transplantation; however, immunosuppression is associated with the development of malignant tumors [1]. Moreover, data on the development of lung cancer after kidney transplantation in patients who are immunosuppressed are limited. Conversely, with technological developments in radiological and surgical fields, less-invasive surgical interventions for small lung tumor are being performed worldwide [2, 3]. This retrospective study evaluates the development of lung cancer in patients who underwent kidney transplantation at a single institution and assesses their outcomes with the aim of improving long-term prognosis after kidney transplantation.

Methods

Study design and patients

We reviewed the clinical data of patients who underwent thoracic surgery after kidney transplantation at the Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital between June 1972 and December 2021. Prior to thoracic surgery, all patients had received a kidney transplant at the same institution and had been advised to quit smoking before the transplantation. All patients underwent thoracic surgery at the same institution where they were diagnosed with lung cancer. The following data were collected: demographic variables, time from kidney transplantation until lung cancer was detected, type of transplanted kidney, smoking habit, diagnosis of lung cancer, types of immunosuppressive treatment, kidney function, histology of lung cancer, clinical and pathologic stage of the disease, types of treatment, complications, survival time, and cause of death. Patients with insufficient or missing clinical information were excluded from this analysis.

Post-kidney transplantation follow-up

All patients who underwent kidney transplantation at the Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital or Masuko Memorial Hospital were followed up. They visited the hospital every 2 weeks for the initial 3 months after kidney transplantation, then every 4 or 5 weeks for the subsequent 9 months, and every 6–9 weeks after 1 year. Immunosuppressive agents were administered from 3 months after kidney transplantation, according to one of four different protocols during the maintenance phase (Table 1) [4–6]. If a malignancy developed, treatment with mycophenolate mofetil (MMF) was discontinued, and everolimus was started for patients who received MMF after kidney transplantation. If everolimus was administered after kidney transplantation, treatment was continued after the malignancy was diagnosed. Chest radiography was performed every 6 months and chest computed tomography (CT) scans were performed every 2 years to screen for thoracic malignancies.Table 1 Protocol on the use of immunosuppressive agents (post-kidney transplant maintenance phase)

FK506 + MMF + PSL	
CsA + MMF + PSL	
CsA + EVR + PSL	
FK506 + EVR + PSL	
Abbreviations: FK506 tacrolimus, MMF mycophenolate mofetil, PSL prednisolone, CyA cyclosporine, EVR, everolimus

Staging of lung cancer

Staging of lung cancer was based on the eighth edition of the TNM classification of lung cancer, as proposed by the Union for International Cancer Control and the International Association for the Study of Lung Cancer in 2017.

Statistical analyses

Descriptive statistics of continuous variables are expressed as the median and categorical variables as the number and percentage. The probability of survival was assessed using the Kaplan–Meier method. Between-groups comparisons were performed using the Mann–Whitney U test for continuous and ordinal variables. P-values of ≤ 0.05 were considered significant. All statistical analyses were performed using EZR.R software, version 2.8-0 (Saitama Medical Center, Jichi Medical University, Saitama, Japan).

Results

Among 2593 patients who underwent kidney transplantation, 2246 received living donor kidney transplants, 315 received cadaveric kidney transplants, 27 underwent simultaneous pancreas–kidney transplantation, and 5 underwent pancreatic transplantation after living donor kidney transplantation. Table 2 summarizes the clinical characteristics of the patients with lung cancer. Lung cancer developed after kidney transplantation in 15 (0.6%) patients (10 men and 5 women, with a median age of 64.0 and an interquartile range of 58.9–74.9 years, at the time of lung cancer diagnosis). Lung cancer was detected on routine chest examination after kidney transplantation in eight patients, by routine chest radiography in two, and by routine chest CT in six. Imaging tests were performed to scrutinize symptoms and other diseases in three patients and lung cancer was discovered incidentally. In one patient, a pulmonary nodule was detected during systemic examination prior to kidney transplantation, and transbronchial lung biopsy was performed. This lung nodule was initially diagnosed as an inflammatory nodule, but after kidney transplantation, the nodule grew, and biopsy was performed again, resulting in a diagnosis of lung cancer. The doses of immunosuppressive agents were reduced after the detection of lung cancer in some patients. In one patient, the dose of MMF was tapered from the time that lung cancer was suspected clinically. It was then discontinued and everolimus was started, but was discontinued because of drug-induced interstitial lung disease, thought to be caused by everolimus. The MMF dose in another patient was reduced by half after lung cancer was diagnosed. He was never treated with everolimus and later died of lung cancer. Patients with up to stage IIIA lung cancer usually underwent surgery. Two patients opted for radiation therapy because of their comorbidities. During the study period, 11 lung tumors in 10 patients were completely resected.Table 2 Characteristics of the patients with lung cancer after kidney transplantation

No.	Age/sex	Duration from KT to lung cancer development (years)	LD/CD	Smoking history	Mode of diagnosis of lung cancer (imaging test)	Clinical TNM (stage)	Histology	Treatment	Pathological TNM (stage)	Survival (months) and cause of death	
1	53/F	34.1	LD	–	Routine (CT)	T1miN0M0 (IA1)	Ad	Surgery (wedge resection)​	T1aN0M0 (IA1)	31: alive	
2​	63/F​	26.5​	CD​	–	Routine (CT)	T1miN0M0 ​(IA1)	Ad​	Surgery(wedge resection)​	T1miN0M0 ​(IA1)	101: alive​	
3​	64/F​	27.1​	CD​	–	Routine (CT)	T1miN0M0 ​(IA1)	Ad​	Surgery (wedge resection)​	TisN0M0​ (0)	36: alive​	
4​	61/M​	17.4​	CD​	+	Symptom​s (CT)	T3N0M0 (IIB)	Ad​	Radiation​	–	3: radiation pneumonitis	
5​	59/M​	13.7​	CD​	+	Incidental detection (CT)​	T1aN0M0​ (IA1)	Unknown​	Radiation​	–	84: myocardial infarction	
6​	64/M​	10.0​	LD​	+	Routine (Xr)	T1bN0M0 (IA2​)	Sq	Surgery (lobectomy)​	T1bN0M0 (IA2)	7: progressive cancer	
7​	56/M​	3.3​	LD​	+	Incidental detection​ (Xr)	T2aN3M0 (IIIB​)	Small	Radiation​	–	3: progressive cancer	
8​	58/M​	7.9​	LD​	+	Routine (CT)	T1bN0M0 (IA2)​	Ad​	Surgery (wedge resection)​	T1bN0M0 (IA2)	41: alive​	
9​	48/F​	3.5​	LD​	+	Routine (CT)​	T1cN0M0 (IA3​)	Sq	Surgery (lobectomy)​	T1cN0M0 (IA3​)	79: alive​	
10​	75/M​	4.0​	LD​	+	Routine (Xr)	T2bN1M0 (IIB)	Sq​	Surgery (bilobectomy)​	T1cN0M0 (IA3​)	51: gastrointestinal tract perforation	
11​	79/M​	5.7​	LD​	–	Symptoms (CT)​	TXNXM1a (IVA​)	Ad​	BSC​	–	Progressive cancera	
12​	73/F​	4.5​	LD​	–	Incidental detection​ (CT)	T1bN0M0 (IA2)​	Ad​	Surgery (segmentectomy)​	T1bN0M0 (IA2)	30: alive​	
13	76/M	1.2	LD	+	Systemic scrutiny prior to KT (CT)	T1cN2M0 (IIIA)	Sq	Surgery (lobectomy)	T2aN0M0 (IB)	66: alive	
14	81/M	2.7	LD	+	Routine (CT)	T1bN0M0 (IA2)	Sq	Surgery (wedge resection)	T1bN0M0 (IA2)	14: second cancer progression	
15	69/M	0.7	LD	+	Symptoms (Xr)	T2aN3M1c (IVB)	Small	Chemotherapy	–	12: progressive cancer	
Abbreviations: KT kidney transplantation, LD living donor, CD cadaveric donor, Xr X-ray, Ad adenocarcinoma, Sq squamous cell carcinoma, small small cell carcinoma, BSC best supportive care

aThe survival period was not described because of BSC

The surgical approaches included eight endoscopic surgeries and two open thoracotomies. Wedge resection (n = 5), segmentectomy (n = 1), lobectomy (n = 3), and bilobectomy (n = 1) were performed. Bilobectomy involved the right middle and lower lobes. Lobectomy involved the right upper, middle, and left lower lobes. Systemic mediastinal lymph node dissection was performed with bilobectomy, lobectomy, and segmentectomy. Patients who underwent lobectomy and bilobectomy, except for one who underwent middle lobectomy, had pericardial fat pad reinforcement at the bronchial stump. In patients with lung cancer who underwent wedge resection or segmentectomy, 18F-fluorodeoxyglucose uptake in the hilar or mediastinal lymph nodes was not observed on preoperative positron emission tomography. Concerning the clinical stage, none of the patients had metastasis in the hilar or mediastinal lymph nodes. Peripheral tumors were resected via wedge resection and central tumors were resected via segmentectomy. Segmentectomy involved the left S4–S5. The pathologic stages were 0 (n = 1), IA1 (n = 2), IA2 (n = 4), IA3 (n = 2), and IB (n = 1).

Table 3 shows the perioperative characteristics of the participants. One patient suffered postoperative bleeding, requiring emergency re-opening of the chest. There were no complications related to the immunosuppressive agents. The median postoperative serum creatinine (Cr) level and estimated glomerular filtration rate (eGFR) after surgery did not differ significantly from those before surgery (Table 4). Postoperatively, even in the immediate perioperative period, none of the patients were reintroduced to dialysis. There were no hospital deaths among patients who underwent surgical resection.Table 3 Perioperative characteristics of the participants

Preoperative serum Cr level (mg/dL)	1.23	(1.17–1.80)	
Preoperative eGFR (mL/min/1.73 m2)	39.0	(29.7–48.4)	
Operative duration (min)	126	(54.6–203.5)	
Volume of blood loss (mL)	4	(0–16.3)	
Complications, n	1		
Postoperative bleeding	1		
Postoperative serum Cr level (mg/dL)	1.18	(1.09–1.47)	
Postoperative eGFR (mL/min/1.73 m2)	42.0	(36.9–50.4)	
Data are presented as medians (interquartile range)

Abbreviations: Cr creatinine, eGFR estimated glomerular filtration rate

Table 4 Pre- and postoperative serum creatinine levels and the estimated glomerular filtration rate

					P-value*	
Serum Cr level (mg/dL)	Preoperative	1.23 (1.17–1.80)	Postoperative	1.18 (1.09–1.47)	0.496	
eGFR (mL/min/1.73 m2)	Preoperative	39.0 (29.7–48.4)	Postoperative	42.0 (36.9–50.4)	0.45	
Data are presented as medians (interquartile range).

Abbreviations: Cr creatinine, eGFR estimated glomerular filtration rate

*P-value based on the Mann–Whitney U test

The surgical group (n = 10) had a significantly better prognosis than the nonsurgical group (n = 4) (P = 0.02) (Fig. 1). Those patients treated with best supportive care were excluded from the nonsurgical group. The median length of follow-up was 33.5 months (range, 3–101 months) for all patients. Recurrence was identified in only one patient from the surgery group. None of the patients received postoperative adjuvant chemotherapy. Two patients without operative indications and those with stage IIIB or more advanced cancer received chemotherapy and radiation therapy. One of two patients with small cell lung cancer received first-line treatment (carboplatin plus etoposide) and second-line therapy (amrubicin monotherapy) without dose reduction. Although he completed chemotherapy without kidney failure, he died of cancer 12 months later. The other patient with small cell lung cancer was treated with palliative radiation for cancer-related pain; however, his liver metastatic lesion grew rapidly, and chemotherapy could not be performed. Thus, he received the best supportive care. Of two patients who had early-stage cancer but were treated with radiation therapy for comorbidities, one died of ischemic heart disease and the other died of radiation pneumonitis.Fig. 1 Kaplan–Meier estimate of the 5-year survival for the surgical and nonsurgical groups

Discussion

We reported the clinical course of 15 patients with lung cancer after kidney transplantation. The lung cancer was detected relatively early during follow-up after kidney transplantation, and curative surgery was performed in 10 of the 15 patients. There were no perioperative complications related to kidney transplantation and the prognosis of the surgical group was favorable.

The overall prognosis was worse for patients with lung cancer who received a solid organ transplant than for those who did not undergo transplantation [7]. Lung cancer after solid organ transplantation was associated with short survival despite surgical resection and radiation therapy. In an Italian multicenter study, the 5-year and 10-year survival rates of 18 patients with lung cancer after kidney transplantation among 3537 kidney transplant recipients were 32.9% and 0%, respectively [8]. Among 2793 patients who underwent kidney transplantation in China, 14 (0.5%) developed lung cancer, and 10 were treated surgically [9]. The overall 5-year survival rate after diagnosis of these 14 patients was 17.9%. The surgical group in our study had a relatively better prognosis because radical surgery was performed for early-stage lung cancer. Another study also found lung cancer surgery after solid organ transplantation to be associated with a high incidence of postoperative complications and a high 90-day postoperative mortality rate [10]. Pneumonia was a common postoperative complication and inflammatory respiratory complications were the only predictor of poor overall survival [11]. The incidence of wound complications can increase after kidney transplantation [12] and lung resection in immunosuppressed patients may also be associated with the risk of bronchopulmonary fistula and other complications. In a previous report from Japan, pneumocystis pneumonia developed in one patient, who required hemodialysis; however, the other patients did not suffer any serious complications [13]. In our study, there were no perioperative complications. Pericardial fat pad reinforcement was performed in most lobectomies; however, further studies are needed to determine its efficacy. In terms of operative methods, the percentage of wedge resections was high. Complete resection with wedge resection can be performed for early-stage small peripheral lung cancer [14]. Lobectomy and mediastinal lymph node dissection are the standard surgical methods for early-stage non-small-cell lung cancer in patients who have undergone kidney transplantation as well as in patients who have not undergone kidney transplantation. Segmentectomy is now considered the standard surgical procedure for patients with small peripheral non-small-cell lung cancer [15]. However, more data should be collected to establish the usefulness of sublobar resection in patients with lung cancer after kidney transplantation. Although none of the patients in the present study received adjuvant therapies, postoperative adjuvant therapy could be considered based on the pathological stage and genetic information as several important studies have been reported recently [16, 17].

At present, there is no consensus on cancer screening protocols, particularly for lung cancer, for patients who have received a solid organ transplant [18]. Yearly low-dose CT is recommended for adults aged 55–79 years who have smoked one pack a day for 30 years or equivalent (two packs a day for 15 years) [19]. Clinicians are often dependent on the clinical practice guidelines of regional and national transplant societies. Despite frequent medical and radiological examinations, lung cancer is usually diagnosed at an advanced stage, and its overall prognosis remains poor [20]. Routine examinations after kidney transplantation were performed based on our own protocol and several cases of early-stage lung cancers were identified. Notably, lung cancer was detected at an early stage in most patients, many of whom underwent curative surgery. Conversely, some patients already had advanced-stage lung cancer at the time of examination. Two patients with symptoms were diagnosed with advanced-stage cancer and had poor prognoses. Thus, routine follow-up after kidney transplantation is important to detect lung cancer before symptoms develop. As lung cancer is difficult to diagnose early, an optimal follow-up protocol must be established in the near future.

The long-term use of immunosuppressive agents accounts for the increased incidence of malignancy after kidney transplantation because immunosuppressive agents reduce the immune surveillance of tumor cells [21]. The Taiwan national database documented a 3.3-fold increase in the overall standardized incidence ratios after kidney transplantation [22]. This study evaluated the number of malignant tumors, including lung tumors that developed during the research period. Among 2593 patients who underwent kidney transplantation at our institution, 206 were found to have a collective 220 (7.9%) tumors, which is higher than in the previous report [23]. Post-transplant lymphoproliferative disorder (n = 33 patients) was the most common malignancy, followed by renal cancer (n = 26), skin cancer (n = 21), colorectal cancer (n = 19), lung cancer (n = 15), gastric cancer (n = 14), breast cancer (n = 14), prostate cancer (n = 13), liver cancer (n = 12), thyroid cancer (n = 11), pancreatic cancer (n = 9), urinary tract cancer (n = 8), uterine cancer (n = 8), tongue cancer (n = 3), pharyngeal cancer (n = 3), esophageal cancer (n = 3), duodenal cancer (n = 3), ovarian cancer (n = 2), brain tumor (n = 2), and carcinoma of unknown primary (n = 1). The true incidence of malignancy after kidney transplantation was challenging to assess accurately because of the long study period and loss of some patients to follow-up. Furthermore, our study had four immunosuppressant protocols, which varied according to the type of immunosuppressive agents used and other factors. Interestingly, the frequency of lung cancer after kidney transplantation in our study was almost the same as that in previous studies [8, 9].

This study has several limitations. First, it was retrospective in nature, so the true incidence of primary lung cancer in the recipients of kidney transplantation could be underestimated. Second, the small sample size of this single-center study did not allow for a multivariate analysis of patient survival. Hence, survival differences have not been interpreted.

In conclusion, routine thoracic examination is recommended for the early detection and treatment of lung cancer in patients who have undergone kidney transplantation. There were no perioperative complications related to thoracic surgery in any of the kidney transplant recipients. Furthermore, radical surgery for early-stage lung cancer may improve the prognosis.

Author contributions

HW conceived the primary hypothesis, designed the research, collected and analyzed the data, and wrote the manuscript. YK analyzed data. SH and HY conceived the primary hypothesis, designed the research, analyzed the data, and edited the manuscript. TH, KF, MO, NG, SN, and YW collected and analyzed the data and edited the manuscript. TFCY supervised the research and edited the manuscript.

Funding

Open Access funding provided by Nagoya University.

Availability of data and materials

Data supporting the findings of this study are available from the corresponding author upon reasonable request.

Declarations

Competing interests

We have no conflicts of interest to declare.

Ethics approval

All procedures were performed based on the ethical standards of the responsible committee on human experimentation (institutional and national) and the 1964 Declaration of Helsinki and subsequent revisions. This retrospective study was based on the medical records of a single institution. It was approved by the Research Ethics Committee of Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital (no. 1583). Written informed consent was not obtained because this study did not require patient consent. None of the patients requested opt-out.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Rama I Grinyó JM Malignancy after renal transplantation: the role of immunosuppression Nat Rev Nephrol 2010 6 511 519 10.1038/nrneph.2010.102 20736984
Rama I, Grinyó JM. Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol. 2010;6:511–9.20736984
2. Chen-Yoshikawa TF Fukui T Nakamura S Ito T Kadomatsu Y Tsubouchi H Current trends in thoracic surgery Nagoya J Med Sci 2020 82 161 174 32581397
Chen-Yoshikawa TF, Fukui T, Nakamura S, Ito T, Kadomatsu Y, Tsubouchi H, et al. Current trends in thoracic surgery. Nagoya J Med Sci. 2020;82:161–74.32581397
3. Chen-Yoshikawa TF Date H Three-dimensional image in lung transplantation Gen Thorac Cardiovasc Surg 2018 66 19 26 10.1007/s11748-017-0849-y 29039137
Chen-Yoshikawa TF, Date H. Three-dimensional image in lung transplantation. Gen Thorac Cardiovasc Surg. 2018;66:19–26.29039137
4. Watarai Y Danguilan R Casasola C Chang SS Ruangkanchanasetr P Kee T Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study Clin Transplant 2021 35 e14415 10.1111/ctr.14415 34216395
Watarai Y, Danguilan R, Casasola C, Chang SS, Ruangkanchanasetr P, Kee T, et al. Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study. Clin Transplant. 2021;35: e14415.34216395
5. Hidaka Y Goto N Yamanaga S Kinoshita K Tanaka K Kawabata C Two-year outcomes of low-exposure extended-release tacrolimus and mycophenolate mofetil regimen in de novo kidney transplantation: A multi-center randomized controlled trial Clin Transplant 2022 36 e14655 10.1111/ctr.14655 35343620
Hidaka Y, Goto N, Yamanaga S, Kinoshita K, Tanaka K, Kawabata C, et al. Two-year outcomes of low-exposure extended-release tacrolimus and mycophenolate mofetil regimen in de novo kidney transplantation: A multi-center randomized controlled trial. Clin Transplant. 2022;36: e14655.35343620
6. Hiramitsu T Okada M Futamura K Yamamoto T Tsujita M Goto N 5-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: retrospective single center assessment Int Immunopharmacol 2016 39 192 198 10.1016/j.intimp.2016.07.019 27491025
Hiramitsu T, Okada M, Futamura K, Yamamoto T, Tsujita M, Goto N, et al. 5-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: retrospective single center assessment. Int Immunopharmacol. 2016;39:192–8.27491025
7. Chen LN Spivack J Cao T Saqi A Benvenuto LJ Bulman WA Characteristics and outcomes of lung cancer in solid organ transplant recipients Lung Cancer 2020 146 297 302 10.1016/j.lungcan.2020.06.018 32619780
Chen LN, Spivack J, Cao T, Saqi A, Benvenuto LJ, Bulman WA, et al. Characteristics and outcomes of lung cancer in solid organ transplant recipients. Lung Cancer. 2020;146:297–302.32619780
8. Tessari G Naldi L Boschiero L Minetti E Sandrini S Nacchia F Incidence of primary and second cancers in renal transplant recipients: a multicenter cohort study Am J Transplant 2013 13 214 221 10.1111/j.1600-6143.2012.04294.x 23057816
Tessari G, Naldi L, Boschiero L, Minetti E, Sandrini S, Nacchia F, et al. Incidence of primary and second cancers in renal transplant recipients: a multicenter cohort study. Am J Transplant. 2013;13:214–21.23057816
9. Zhang SX Liu Y Primary lung cancer in Chinese renal transplant recipients: a single-center analysis Nan Fang Yi Ke Da Xue Xue Bao 2017 37 715 720 28669942
Zhang SX, Liu Y. Primary lung cancer in Chinese renal transplant recipients: a single-center analysis. Nan Fang Yi Ke Da Xue Xue Bao. 2017;37:715–20.28669942
10. Drevet G Duruisseaux M Maury JM Riche B Grima R Ginoux M Lung cancer surgical treatment after solid organ transplantation: a single center 30-year experience Lung Cancer 2020 139 55 59 10.1016/j.lungcan.2019.10.023 31739183
Drevet G, Duruisseaux M, Maury JM, Riche B, Grima R, Ginoux M, et al. Lung cancer surgical treatment after solid organ transplantation: a single center 30-year experience. Lung Cancer. 2020;139:55–9.31739183
11. Kadomatsu Y Tsubouchi H Nakanishi K Sugiyama T Ueno H Goto M Differential impacts of postoperative complications on patients’ survival in completely resected non-small-cell lung cancer Gen Thorac Cardiovasc Surg 2021 69 1283 1290 10.1007/s11748-021-01619-z 33687642
Kadomatsu Y, Tsubouchi H, Nakanishi K, Sugiyama T, Ueno H, Goto M, et al. Differential impacts of postoperative complications on patients’ survival in completely resected non-small-cell lung cancer. Gen Thorac Cardiovasc Surg. 2021;69:1283–90.33687642
12. Nashan B Citterio F Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature Transplantation 2012 94 547 561 10.1097/TP.0b013e3182551021 22941182
Nashan B, Citterio F. Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature. Transplantation. 2012;94:547–61.22941182
13. Maeda H Kanzaki M Sakamoto K Kikkawa T Isaka T Oyama K Video-assisted thoracoscopic surgery after renal transplantation: a single-institution experience Asian J Endosc Surg 2016 9 37 43 10.1111/ases.12248 26486097
Maeda H, Kanzaki M, Sakamoto K, Kikkawa T, Isaka T, Oyama K, et al. Video-assisted thoracoscopic surgery after renal transplantation: a single-institution experience. Asian J Endosc Surg. 2016;9:37–43.26486097
14. Yoshino I Moriya Y Suzuki K Wakabayashi M Saji H Aokage K Long-term outcome of patients with peripheral ground-glass opacity-dominant lung cancer after sublobar resections J Thorac Cardiovasc Surg 2023 166 1222 1231 10.1016/j.jtcvs.2023.01.019 37704343
Yoshino I, Moriya Y, Suzuki K, Wakabayashi M, Saji H, Aokage K, et al. Long-term outcome of patients with peripheral ground-glass opacity-dominant lung cancer after sublobar resections. J Thorac Cardiovasc Surg. 2023;166:1222–31.37704343
15. Saji H Okada M Tsuboi M Nakajima R Suzuki K Aokage K Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial Lancet 2022 399 1607 1617 10.1016/S0140-6736(21)02333-3 35461558
Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022;399:1607–17.35461558
16. Felip E Altorki N Zhou C Csőszi T Vynnychenko I Goloborodko O Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial Lancet 2021 398 1344 1357 10.1016/S0140-6736(21)02098-5 34555333
Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398:1344–57.34555333
17. Wu YL Tsuboi M He J John T Grohe C Majem M Osimertinib in resected EGFR-mutated non-small-cell lung cancer N Engl J Med 2020 383 1711 1723 10.1056/NEJMoa2027071 32955177
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383:1711–23.32955177
18. Dharia A Boulet J Sridhar VS Kitchlu A Cancer screening in solid organ transplant recipients: a focus on screening liver, lung, and kidney recipients for cancers related to the transplanted organ Transplantation 2022 106 e64 e65 10.1097/TP.0000000000003773 33795594
Dharia A, Boulet J, Sridhar VS, Kitchlu A. Cancer screening in solid organ transplant recipients: a focus on screening liver, lung, and kidney recipients for cancers related to the transplanted organ. Transplantation. 2022;106:e64–5.33795594
19. Al-Adra D Al-Qaoud T Fowler K Wong G De Novo malignancies after kidney transplantation Clin J Am Soc Nephrol 2022 17 434 443 10.2215/CJN.14570920 33782034
Al-Adra D, Al-Qaoud T, Fowler K, Wong G. De Novo malignancies after kidney transplantation. Clin J Am Soc Nephrol. 2022;17:434–43.33782034
20. Rousseau-Gazaniol C Fraboulet S Couderc LJ Kreis H Borie R Tricot L Lung cancer in renal transplant recipients: a case-control study Lung Cancer 2017 111 96 100 10.1016/j.lungcan.2017.07.011 28838407
Rousseau-Gazaniol C, Fraboulet S, Couderc LJ, Kreis H, Borie R, Tricot L, et al. Lung cancer in renal transplant recipients: a case-control study. Lung Cancer. 2017;111:96–100.28838407
21. Martinez OM de Gruijl FR Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients Am J Transplant 2008 8 2205 2211 10.1111/j.1600-6143.2008.02368.x 18801025
Martinez OM, de Gruijl FR. Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients. Am J Transplant. 2008;8:2205–11.18801025
22. Tsai HI Lee CW Kuo CF See LC Liu FC Chiou MJ De novo malignancy in organ transplant recipients in Taiwan: a nationwide cohort population study Oncotarget 2017 8 36685 36695 10.18632/oncotarget.13124 27821818
Tsai HI, Lee CW, Kuo CF, See LC, Liu FC, Chiou MJ, et al. De novo malignancy in organ transplant recipients in Taiwan: a nationwide cohort population study. Oncotarget. 2017;8:36685–95.27821818
23. Shen B Cen Z Tan M Song C Wu X Wang J Current status of malignant tumors after organ transplantation Biomed Res Int 2022 10.1155/2022/5852451 36588538
Shen B, Cen Z, Tan M, Song C, Wu X, Wang J, et al. Current status of malignant tumors after organ transplantation. Biomed Res Int. 2022. 10.1155/2022/5852451.36588538
